Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of polydatin in preparation of medicine for treating pulmonary arterial hypertension

A technology of pulmonary arterial hypertension and polydatin, which is applied in the field of biomedicine, can solve the problems of no use of polydatin, high price, inability to target vascular remodeling, right heart hypertrophy, etc., so as to reduce the right heart hypertrophy index and reduce muscle type thickening. , the effect of expanding the diameter of the vascular lumen

Pending Publication Date: 2022-01-21
重庆市急救医疗中心
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] (1) There are currently no pulmonary hypertension drugs that target vascular remodeling and right heart hypertrophy
[0006] (2) The prior art does not apply polydatin in the preparation of medicines for the treatment of pulmonary arterial hypertension.
[0007] (3) The current clinical drugs for the treatment of pulmonary hypertension are not only expensive, but also cannot target vascular remodeling and right heart hypertrophy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of polydatin in preparation of medicine for treating pulmonary arterial hypertension
  • Application of polydatin in preparation of medicine for treating pulmonary arterial hypertension
  • Application of polydatin in preparation of medicine for treating pulmonary arterial hypertension

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0048] 1. Materials

[0049] 1.1 Drugs and reagents: polydatin (Sichuan Weikeqi Biotechnology Co., Ltd.), monocrotaline (Sichuan Weikeqi Biotechnology Co., Ltd.), sildenafil citrate (Jilin Jinheng Pharmaceutical Co., Ltd.) , 4% paraformaldehyde (Biosharp), hematoxylin-eosin staining kit (Solarbio G1120), 0.5% CMCNa (Dalian Meilun).

[0050] 1.2 Animals SPF-grade male SD rats (170-190g) were purchased from Beijing Weitong Lihua Experimental Animal Technology Co., Ltd., animal license number: SCXK (Beijing) 2016-0006.

[0051] 1.3 Instrument electronic balance (Biyuntian E0242), pathological slicer (LEICA RM2015)

[0052] 2. Method

[0053] Get 40 SD rats (SPF grade, 200 ± 20g) males, divide into blank group, model group, positive group (sildenafil), low dose group (polydatin 30mg / kg), high dose group ( polydatin 60mg / kg), 8 rats in each group. After 4 days of adaptive feeding, except for the rats in the blank group, the model was established. A single injection of MCT (60 m...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the technical field of biological medicines, and discloses application of polydatin in preparation of a medicine for treating pulmonary arterial hypertension, and application of the polydatin in preparation of a medicine for inhibiting pulmonary vascular remodeling and right heart hypertrophy to treat pulmonary arterial hypertension. The pulmonary arterial hypertension in the invention is represented by right heart hypertrophy and pulmonary vascular remodeling. The dosage of the polydatin disclosed by the invention is 30 mg / kg to 60 mg / kg. The invention provides pharmaceutical application of the polydatin in treating pulmonary arterial hypertension by improving right heart hypertrophy and pulmonary vascular remodeling. The polydatin has a remarkable inhibiting effect on pulmonary vascular remodeling and right heart hypertrophy, and can remarkably reduce the thickness of a pulmonary artery vascular wall, relieve muscle type thickening of a blood vessel middle layer and enlarge the diameter of a vascular cavity, so that the pulmonary artery pressure is reduced; the weight of the right ventricle can be obviously reduced; the right heart hypertrophy index is obviously reduced; and it is prompted that the polydatin has large potential and distant view in excavating and developing of preparation of the targeted medicine for treating pulmonary vascular remodeling.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, and in particular relates to the use of polydatin in the preparation of medicines for treating pulmonary hypertension. Background technique [0002] Currently, pulmonary arterial hypertension (PAH) is a chronic disease characterized by abnormally high pulmonary artery pressure caused by pulmonary vascular stenosis or increased resistance. It has obvious pathological features of pulmonary vascular remodeling and right heart hypertrophy, and may develop into right heart failure later Even death, its clinical symptoms have no significant features, manifested as chest tightness, fatigue, dizziness, dyspnea, etc. Epidemiological studies have shown that the incidence is skewed towards the elderly and women, and the mortality rate is higher. Right heart hypertrophy and pulmonary vascular remodeling are important causes of right heart failure and death. At present, there are few therapeutic drugs f...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7034A61P11/00A61P9/12A61P9/00
CPCA61K31/7034A61P11/00A61P9/12A61P9/00
Inventor 郑晓媛余志杰陈兴
Owner 重庆市急救医疗中心
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com